Program table - The 3rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy)

The 3rd World Congress on
Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy)
Hilton Hotel, Prague, Czech Republic, May 13-16, 2010

Program table

Friday, May 14, 2010

Hall A

Hall B

Hall C

08:30-10:00

Plenary Session 1

Chairpersons: S. Del Prato, I. Raz

INVITED SCIENTIST

Cellular mechanisms of insulin resistance: Implications for obesity, lipodystrophy, type 2 diabetes (T2D)

and the metabolic syndrome

G.I. Shulman

What can we learn from the new ACCORD sub analysis?

H. Ginsberg

Need for outcome studies in diabetic drug development

10:00-10:30

Coffee break

10:30-12:30

Session 2

GLP-1 RECEPTOR AGONISTS AND DPP-4 INHIBITORS: A CLINICAL COMPARISON
Glycaemic control impact on body weight potential to reduce CV risk

GLP-1: G. Sesti

DPP-4: I. Raz

Beta-cell protection

Animal studies: M. Donath

Human perspective: E. Ferrannini

Session 3
OPTIMAL BLOOD PRESSURE CONTROL

The blood pressure legacy

Pro: L. Ruilope

Con: G. Parati

Blood pressure: The lower, the better

Pro: G. Mancia

Con: A. Zanchetti

Session 4

OBESITY: CAUSE AND DIFFERENT APPROACHES
Socioeconomic / depression as common soil for obesity

Should obesity be treated at any age?

R. Bonadonna

Physical exercise. How and how much?

P. de Feo

Effective diet for weight loss

12:30-13:15

Lunch break

13:15-14:00

Plenary Session 5

14:00-16:00

Session 6

Chairperson: J. Meigs

THERAPY IN THE EARLY STAGE
Pharmacologic prevention of T2DM

Pro: R.A. DeFronzo

Con: J. Tuomilehto
Metformin failed: What's next?

Incretins: S. Del Prato

Others: G.B. Bolli

Session 7

HYPERTENSION TREATMENT
ACE-inhibition and CV protection: The role of metabolic profile

G. Viberti

Diuretics treatment of hypertension
Pro: E. Grossman

Con: P. Verdecchia

Session 8

Chairpersons: E. Ferrannini, M. Petkova

GLUCOSE VARIABILITY

Postprandial glucose and glucose variability: Should we care?
Pro: A. Ceriello

Con: E. Standl

Continuous glucose monitoring (closing the loop)

Expectations: M. Philip

Humbles: J.H. de Vries

16:00-16:30

Coffee break

16:30-18:30

Session 9

T2D IN CHILDHOOD

Epidemiology and pathophysiology
S. Caprio

The accelerator hypothesis and the double diabetes

P. Pozzilli
Treatment of T2D in youth: What's on the Horizon?

S. Arslanian

Session 10

RAS AND COMPLICATIONS
eGFR or albuminuria
predictor for renal and CV outcome
eGFR: M. Ravid

Albuminuria: D. de Zeeuw

RAS blockade for every diabetic
Pro:

Con: A. Solini

The place of multiple RAS Blockade

L. Gnudi

Session 11

Chairperson: S. Stehouwer

VESSELS, ENDOTHELIUM AND METABOLIC DISEASES
Inflammation

J.M. Real-Fernandez
The role of metalloproteinases: At the interface between metabolic and inflammatory disorders

M. Federici

Vascular disease in diabetes: The role of repatory mechanisms

A. Avogaro

Endothelial factors and diabetic nephropathy

Saturday, May 15, 2010

Hall A

Hall B

Hall C

08:30-10:00

Session 12

Chairpersons: P. Home, H. Toplak

LIPIDS IN THE WRONG PLACE
Islet fat

E. Ravussin
Intramyocellular

R.A. DeFronzo

Visceral fat/ NASH

G. Perseghin
Myocardial/Perivascular/ Epicardical fat

P. Iozzo

Session 13

THERAPY IN COMPLEX PATIENTS WITH TYPE 2 DIABETES CURRENT LIMITATIONS & FUTURE TREATMENT OPTIONS
Chairpersons: G. Jermendy H. Lebovitz
Elderly T2DM

Renally impaired T2DM
E. Ritz
T2DM with vascular complications: Which target? Which treatment?
B. Charbonnel
Multidrug treatment of T2DM, a challenge for compliance
S. Del Prato

Session 14

BARIATRIC SURGERY FOR T2DM REVERSAL
The evidence

G. Schernthaner
The mechanism

E. Ferrannini
The risk

A. Keidar
The future

F. Rubino

10:00-10:30

Coffee break

10:30-12:30

Session 15

Chairperson: J. Skrha

HYPOGLYCEMIA AND CV RISKS
Hypoglycemia and CV risks

B. Frier

ACCORD, ADVANCE and VADT

G. Schernthaner

Hypoglycaemia and it's potential contribution to fatal cardiac arrhythmias in T1D and T2D
S. Heller

Session 16

Chairpersons: G.B. Bolli, R. Fagard

INSULIN THERAPY
Insulin therapy in type 2 diabetes
Not too soon: H. Lebovitz

Not too late: L. Meneghini
HbA1c targets should be individualized for all patients with DM

Pro: L. Leiter

Con: P. Home

Session 17

Chairperson: H. Rosolova

PREVENTION OF CVD
Diabetic dyslipidemia
statin Vs. combination therapy
Pro: R. Bitzur

Con: A. Zambon
Risk assessment of universal treatment
Assessment: J. Meigs

Treatment:

12:30-13:15

Lunch break

13:15-14:00

Plenary Session 18

14:00-16:00

Session 19

Chairperson: E. Bonora

SAFETY – OPEN QUESTIONS
Incretins

Sulfonylurea

J. Davidson
PPAR-agonists

P. Home
Insulin

G.B. Bolli

Session 20

Chairperson: L. Meneghini
NOVEL DRUGS FOR DIABETES
Novel mechanisms for the treatment of T2DM

H. Katzeff

The role of bile acid in T2D treatment
Y. Handelsman

Anticoagulatation for every diabetic? Pro:

Con: A. Nicolucci

Session 21

SMOKING CESSATION - GET READY FOR SUCCESS!

Chairperson: P.M. Nilsson

Evolutionary perspectives on addiction leading to smoking, obesity and drug abuse

P.M. Nilsson
Nicotine dependence: Why, how and when?

K.O. Fagerström
Th global epidemic smoking cessation strategies. The evidence

R. Fagard
Non-pharmacological support and counseling

P. Tønnesen
PANEL DISCUSSION

16:00-16:30

Coffee break

16:30-18:30

Session 22

Chairperson: M. Shestakova

HYPERGLYCEMIA AND CVD
Is hyperglycemia a CV risk factor?
Pro: M. Hanefeld

Con: A. Natali

Heart in diabetes
A macrovascular disease:

D. Tschoepe

A microvascular disease:

M. Laakso

Session 23

Chairperson: N.M. Lalic, R.A. deFronzo

PHARMACOLOGICAL APPROACHES TO THE MANAGEMENT OF OBESITY
Benefits of control of calorie intake

N. Stern
Mechanisms of medications

Comparative efficiency and safety
V. Hainer

Sibutramine on CV outcome

A. Scheen

Session 24

Chairperson: J.P. Després

THE CARDIOMETABOLIC BENEFITS OF MODERATE WEIGHT LOSS
Obesity management: Beyond weight loss
R. Ross

Reducing visceral adiposity/ ectopic fat: A better therapeutic target than weight loss?

J.P. Després

Variation in body weight associated with hypoglycaemic medication: more than a side effect in type 2 diabetes

Novel hypoglycemic agents inducing weight loss

Sunday, May 16, 2010

Hall A

Hall B

Hall C

08:30-10:00

Session 25

Chairperson: H. Ilkova

HYPERTENSION IN DIABETES
Vascular disease endothelial function and clinical implication
A. Natali
Endothelium: Target for therapy
T. Lüscher
Microvascular dysfunction as a central factor linking obesity to diabetes and hypertension
C. Stehouwer

Session 26

Chairperson: E. Standl

CARDIOVASCULAR RISK FACTORS
Should CRP be a target of therapy?

L.A. Leiter
A1C Debate
Pro: E. Bonora

Con: J. Tuomilehto

10:00-10:30

Coffee break

10:30-12:30

Session 27

Chairperson: I. Raz

FUTURE THERAPY OF T2D
GK Activator: F. Matschinsky

SGLT2: E. Boutati

Long Acting GLP1: A. Garber

Long Acting Insulin:

Glucagon antagonists: K. Petersen